232 related articles for article (PubMed ID: 29893941)
1. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A
Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941
[TBL] [Abstract][Full Text] [Related]
2. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
3. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
[TBL] [Abstract][Full Text] [Related]
4. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
[TBL] [Abstract][Full Text] [Related]
5. Medication adherence among patients with gout: A systematic review and meta-analysis.
Scheepers LEJM; van Onna M; Stehouwer CDA; Singh JA; Arts ICW; Boonen A
Semin Arthritis Rheum; 2018 Apr; 47(5):689-702. PubMed ID: 29198878
[TBL] [Abstract][Full Text] [Related]
6. Adherence with urate-lowering therapies for the treatment of gout.
Harrold LR; Andrade SE; Briesacher BA; Raebel MA; Fouayzi H; Yood RA; Ockene IS
Arthritis Res Ther; 2009; 11(2):R46. PubMed ID: 19327147
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol adherence among patients with gout: an Italian general practice database study.
Mantarro S; Capogrosso-Sansone A; Tuccori M; Blandizzi C; Montagnani S; Convertino I; Antonioli L; Fornai M; Cricelli I; Pecchioli S; Cricelli C; Lapi F
Int J Clin Pract; 2015 Jul; 69(7):757-65. PubMed ID: 25683693
[TBL] [Abstract][Full Text] [Related]
8. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
[TBL] [Abstract][Full Text] [Related]
9. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
[TBL] [Abstract][Full Text] [Related]
10. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
11. Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions.
Coleshill MJ; Day RO; Tam K; Kouhkamari M; Caillet V; Aung E; Kannangara DRW; Cronin P; Rodgers A; Stocker SL
Br J Clin Pharmacol; 2022 Nov; 88(11):4894-4901. PubMed ID: 35675118
[TBL] [Abstract][Full Text] [Related]
12. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
Mikuls TR; Cheetham TC; Levy GD; Rashid N; Kerimian A; Low KJ; Coburn BW; Redden DT; Saag KG; Foster PJ; Chen L; Curtis JR
Am J Med; 2019 Mar; 132(3):354-361. PubMed ID: 30503879
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
[TBL] [Abstract][Full Text] [Related]
14. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
15. Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
So MW; Kim AR; Lee SG
Int J Rheum Dis; 2023 Sep; 26(9):1770-1778. PubMed ID: 37431263
[TBL] [Abstract][Full Text] [Related]
16. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
17. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
18. Gout medication treatment patterns and adherence to standards of care from a managed care perspective.
Sarawate CA; Brewer KK; Yang W; Patel PA; Schumacher HR; Saag KG; Bakst AW
Mayo Clin Proc; 2006 Jul; 81(7):925-34. PubMed ID: 16835972
[TBL] [Abstract][Full Text] [Related]
19. Allopurinol adherence, persistence and patterns of use in individuals with diabetes and gout: A retrospective, population-based cohort analysis.
Weisman A; Tomlinson GA; Lipscombe LL; Perkins BA; Hawker GA
Semin Arthritis Rheum; 2021 Dec; 51(6):1162-1169. PubMed ID: 34555659
[TBL] [Abstract][Full Text] [Related]
20. Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study.
Slobodnick A; Toprover M; Greenberg J; Crittenden DB; Pike VC; Qian Y; Zhong H; Pillinger MH
Medicine (Baltimore); 2020 Aug; 99(35):e21675. PubMed ID: 32871882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
